Anti-complement drugs for the treatment of geographic atrophy and the release of silicone oil

被引:0
|
作者
Melo, Gustavo Barreto [1 ]
Emerson, Geoffrey Guy [2 ]
机构
[1] Univ Fed Sao Paulo, Dept Ophthalmol, Rua Botucatu 820, Sao Paulo, Brazil
[2] Univ Minnesota, Dept Ophthalmol, Minneapolis, MN USA
关键词
Avacincaptad pegol; Pegcetacoplan; Geographic atrophy; Silicone oil; Syringe; SYRINGES;
D O I
10.1186/s40942-023-00523-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Intravitreal injections are a common procedure in ophthalmology, often using syringes coated with silicone to aid piston movement and needles coated with silicone oil to facilitate penetration of the sclera. Pegcetacoplan and avacincaptad pegol, recently approved for clinical use by the US Food and Drug Administration, have higher viscosity and seem more susceptible to entrap air bubbles compared to anti-VEGF drugs.It is plausible that both anti-complement drugs could be associated with a higher likelihood of introducing silicone oil in the vitreous because of higher viscosity, with potentially higher friction at the inner surface of syringe barrel, in the vicinity of silicone oil. In addition to this, undesirable agitation might be inadvertently promoted by some retina specialists to remove air bubbles from the drug solution.In conclusion, recent reports of silicone oil droplets in the vitreous of patients receiving pegcetacoplan injection might be related to both its viscosity and to agitation of the syringe to remove air bubbles. Since avacincaptad pegol also is viscous, though with different pH, syringe and filter needle, we might expect similar reports for this agent soon. We also recommend further studies be carried not only to clarify the current matter but also the potential association between the combination of agitation, silicone oil and inflammation or any immune response.
引用
收藏
页数:3
相关论文
共 44 条
  • [41] CONTAMINATION OF ANTI-VEGF DRUGS FOR INTRAVITREAL INJECTION How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?
    Schargus, Marc
    Werner, Benjamin P.
    Geerling, Gerd
    Winter, Gerhard
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (10): : 2088 - 2095
  • [42] Oral Administration of the Complement Factor D Inhibitor Danicopan (ALXN2040) in Preclinical Studies Demonstrates High and Sustained Drug Concentrations in Posterior Ocular Tissues for the Potential Treatment of Geographic Atrophy
    Boyer, David
    Rivera, Jose
    Ko, Ya-Ping
    Podos, Steven
    Cartwright, Mark
    Gao, Xiang
    Wiles, Jason
    Huang, Mingjun
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [43] DESIGN AND RATIONALE OF A CLINICAL TRIAL TO MEASURE THE DEVELOPMENT OF GEOGRAPHIC ATROPHY IN PATIENTS UNDERGOING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION: THE RIVAL STUDY
    Gillies, Mark
    Hunyor, Alex
    Woodcock, Chad
    Walsh, Meagan
    Kurstjens, Nicol
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 113 - 113
  • [44] Enhanced release of prostaglandin D2 during re-incubation of RAW 264.7 macrophage-like cells after treatment of both lipopolysaccharide and non-steroidal anti-inflammatory drugs
    Tanaka, Y
    Takizawa, M
    Igimi, S
    Amano, F
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (07) : 985 - 991